{"PubmedArticle": [{"MedlineCitation": {"InvestigatorList": [], "SpaceFlightMission": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "OtherID": [], "PMID": "16374851", "DateCompleted": {"Year": "2006", "Month": "04", "Day": "06"}, "DateRevised": {"Year": "2013", "Month": "11", "Day": "21"}, "Article": {"Language": ["eng"], "ELocationID": [], "ArticleDate": [], "Journal": {"ISSN": "0022-3549", "JournalIssue": {"Volume": "95", "Issue": "2", "PubDate": {"Year": "2006", "Month": "Feb"}}, "Title": "Journal of pharmaceutical sciences", "ISOAbbreviation": "J Pharm Sci"}, "ArticleTitle": "Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin.", "Pagination": {"StartPage": "256", "EndPage": "267", "MedlinePgn": "256-67"}, "Abstract": {"AbstractText": ["The pharmacokinetic profile and renal clearance of a novel synthetic ozonide antimalarial (1) was found to be significantly altered when intravenously administered to rats as a cyclodextrin-based formulation (0.1 M Captisol, a sulfobutylether beta-cyclodextrin derivative (SBE(7)-beta-CD)) compared to a cyclodextrin-free isotonic buffered glucose formulation. There was an 8.5-fold decrease in the steady-state blood volume of distribution, a 6.6-fold decrease in the mean residence time and a greater than 200-fold increase in renal clearance of 1 when administered in the cyclodextrin formulation. Analysis of the whole blood and plasma concentration profiles revealed an essentially constant blood to plasma ratio when 1 was administered in the cyclodextrin-free formulation, whereas this ratio changed as a function of time when administered in the presence of the cyclodextrin derivative. It is postulated that the observed differences were due to a very strong complexation interaction between 1 and the cyclodextrin, resulting in a slow dissociation of the complex in vivo, and altered distribution and excretion profiles. Preliminary studies using isothermal titration calorimetry (ITC) indicated that the association constant for the 1/Captisol complex was approximately two orders of magnitude higher than reported for typical drug/cyclodextrin complexes."], "CopyrightInformation": "Copright 2005 Wiley-Liss, Inc."}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Centre for Drug Candidate Optimisation, Victorian College of Pharmacy, Monash University (Parkville Campus), Parkville, Victoria, Australia. susan.charman@vcp.monash.edu.au"}], "Identifier": [], "LastName": "Charman", "ForeName": "Susan A", "Initials": "SA"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Perry", "ForeName": "Christine S", "Initials": "CS"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Chiu", "ForeName": "Francis C K", "Initials": "FC"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "McIntosh", "ForeName": "Kylie A", "Initials": "KA"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Prankerd", "ForeName": "Richard J", "Initials": "RJ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Charman", "ForeName": "William N", "Initials": "WN"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Pharm Sci", "NlmUniqueID": "2985195R", "ISSNLinking": "0022-3549"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antimalarials"}, {"RegistryNumber": "0", "NameOfSubstance": "Cyclodextrins"}, {"RegistryNumber": "0", "NameOfSubstance": "Pharmaceutical Preparations"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemical synthesis", "pharmacokinetics", "urine"], "DescriptorName": "Antimalarials"}, {"QualifierName": [], "DescriptorName": "Calorimetry"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Cyclodextrins"}, {"QualifierName": [], "DescriptorName": "Injections, Intravenous"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Molecular Conformation"}, {"QualifierName": ["chemistry"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Pharmaceutical Preparations"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}, {"QualifierName": [], "DescriptorName": "Reproducibility of Results"}, {"QualifierName": [], "DescriptorName": "Time Factors"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2005", "Month": "12", "Day": "24", "Hour": "9", "Minute": "0"}, {"Year": "2006", "Month": "4", "Day": "7", "Hour": "9", "Minute": "0"}, {"Year": "2005", "Month": "12", "Day": "24", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["16374851", "10.1002/jps.20534", "S0022-3549(16)31946-3"]}}], "PubmedBookArticle": []}